About Corimmun Exit

Corimmun is a drug-developing biotech company which focuses on personalized medicine in cardiovascular diseases. We concentrate on innovative peptide and biological drugs in indications with unmet medical needs.

Exit since June 2012.

Press releases

26. July 2012

Investors Realize exit VIA Trade Sale of Portfolio Company Corimmun GmbH

Following the sale of their portfolio company CorImmun GmbH to Janssen-Cilag for an undisclosed upfront payment and a contingent future clinical milestone payment, Corimmun’s investors led by MIG have realized an important return on investment. CorImmun’s lead compound, COR-1, is a small cyclic peptide currently in early clinical development for the treatment of heart failure. COR-1 has been shown in preclinical studies to improve heart function by decreasing autoimmune, beta 1 receptor-s
22. September 2008

Corimmun GmbH closes a EUR 5million financing round with MIG AG as lead investor

The biotech company Corimmun GmbH has successfully closed a series A financing with EUR 5 million. The company which is specialized in inflammatory mechanisms in cardiovascular diseases received seed-financing from High-Tech Gründerfonds and Bayernkapital in 2006. This current investment will enable Corimmun to develop the lead product COR-1 until proof of principle in man in phase II. The product pipeline will be further expanded and developed. COR-1 is a peptide-drug, which inhibits the au

Info & Contact

Dr. Götz Münch


Fraunhoferstr. 17
82152 Martinsried

In portfolio

29. Dec 2006 – 22. Jun 2012

Marco Winzer